A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy?

Critical Reviews in Immunology

Volumn 21, Issue 1-3, 2001, Pages 249-261

  Tasch, Jason ^a   Gong, Mike ^b   Sadelain, Michel ^b   Heston, Warren D W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Immunotherapy; Prostate; PSMA

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; CANCER VACCINE; CAPROMAB PENDETIDE IN 111; GAMMA GLUTAMYL HYDROLASE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ALTERNATIVE RNA SPLICING; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; DRUG TARGETING; GENE CONTROL; GROWTH REGULATION; HORMONE DEPENDENCE; HUMAN; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; TISSUE DISTRIBUTION;

ALTERNATIVE SPLICING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BINDING SITES; CANCER VACCINES; CARBOXYPEPTIDASES; CLONING, MOLECULAR; GENE THERAPY; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0034797419     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostate cancer patients
2. LNCaP model of human prostatic carcinoma
3. Capromab pendetide imaging of prostate cancer
4. Immunoscintigraphy with Indium-111-capromab pendetide evaluation before definitive therapy ion patients with prostate cancer
5. 111-Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
6. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from the antiporstate monoclonal antibody 7E11C.5
7. Prostate cancer and prostate bed SPECT imaging with Prostascint: Semiquantitative correlation with prostatic biopsy results
8. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen
9. Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endotheilium
10. Development of PSMA-based immunotherapies for prostate cancer
11. Molecular cloning of a complimentary DNA encoding a prostate-specific membrane antigen
12. Expression of the prostate-specific membrane antigen
13. Alternatively spliced variants of prostate-specific membrane antigen RNA, ratio of expression as a potential measurement of progression
14. Identification, purification, and sub-cellular localization of prostate specific membrane antigen PSM protein in the LNCaP prostatic carcinoma cell line
15. Mapping, genomic organization, and promoter analysis of the human prostate-specific membrane antigen gene
16. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADASE/folate hydrolase
17. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells
18. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase
19. Molecular characterization of human brain N-acetylated alpha linked acidic dipeptidase (NAALADASE)
20. Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library
21. Prostate-specific membrane antigen expression in normal, benign and malignant human tissues
22. Structure of membrane glutamate carboxypeptidase
23. Cocatalytic zinc motifs in enzyme catalysis
24. Constituitive and antibody-induced internalization of prostate-specific membrane antigen
25. Characterization of hydrolytic and endocytic activities of prostate-specific membrane antigen
26. In vitro characterization of radiolabeled monodonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
27. An alpha partide emitting antibody Bi-213 J591 for radioimmunotherapy of prostate cancer
28. Inhibition of prostate tumor cell adhesion by targeting prostate specific membrane antigen
29. Overview of evolving strategies incorporating prostate-specific membrane antigen as a target for therapy
30. Characterization of the enzymatic activity of PSM, comparison with brain NAALADase
31. A tissue-specific enhancer of the prostate specific membrane antigen gene
32. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
33. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen (PSMA) promoter/enhancer
34. Isolation and characterization of PAGE 1 and GAGE 7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens
35. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database
36. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor associated neovasculature
37. Prostate-specific membrane antigen is produced in tumor-associated neovasculature
38. Prostate-specific membrane antigen in breast carcinoma
39. Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man-clinical trials at Memorial Sloan-Kettering Cancer Center
40. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial
41. Infusion of dendritic cells pulsed with HLA-A2 specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
42. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen
43. In vivo eradication of prostate cancer tumors in SCID mice using Pz-1 genetically modified human T cells
44. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers
45. Selection of tumor antigens as targets for immune attack using immunohistochemistry: Protein antigens